Showing 7031-7040 of 10817 results for "".
- Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meetinghttps://practicaldermatology.com/news/dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting/2459916/Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washing
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab
- Vyome Secures $22M to Advance Dermatology Pipelinehttps://practicaldermatology.com/news/vyome-secures-22m-to-advance-dermatology-pipeline/2459918/Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 19
- 2019 Residents of Distinction Return from Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/2019-residents-of-distinction-return-from-caribbean-dermatology-symposium/2459919/Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The reside
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne
- Peak Health Launches Plant-Based Regenerative Skincare Linehttps://practicaldermatology.com/news/peak-health-launches-plant-based-regenerative-skincare-line/2459940/Peak Health, launched Curere, a patented, regenerative skin care line created to treat a range of skin conditions, including acne, third-degree burns and necrosis. The line is made from all-natural ingredients to penetrate the dermal layer of skin and activate stem cells while also facili
- “Outstanding Clearance Rates” for Sebaceous Hyperplasia Facial Lesions Seen with NPShttps://practicaldermatology.com/news/outstanding-clearance-rates-for-sebaceous-hyperplasia-facial-lesions-seen-with-nps/2459943/Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology achieved “outstanding clearance rates” on sebaceous hyperplasia lesions on the face, the company reports. Initial data indicate that 221 of 222 (99.5 percent
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Bristol-Myers Squibb to Acquire Celgenehttps://practicaldermatology.com/news/bristol-myers-squibb-to-acquire-celgene/2459948/Bristol-Myers Squibb Company will acquire Celgene Corp. in a cash and stock transaction with an equity value of approximately $74 billion. The combined company with complementary areas of focus, will opera
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G